Silicogenix provides a programmable drug‑design platform that assembles pre‑generated chemical‑building‑blocks into custom small‑molecule or peptide ligands, called Target‑Ligand Pairs (TLPs), enabling rapid creation of proteome‑wide chemical knockouts. The system delivers biologically active candidates in weeks for under $5,000, supporting pharmaceutical, biotech, and academic programs that require fast, cost‑effective development of personalized therapeutics for rare diseases and heterogeneous targets.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery relies on lengthy, costly synthesis cycles and often produces one-size-fits-all molecules that cannot address the molecular heterogeneity of individual patients or rare disease targets.
Solution
Silicogenix offers a programmable drug‑design platform that assembles pre‑generated chemical‑building‑blocks into custom small‑molecule or peptide ligands, termed Target‑Ligand Pairs (TLPs). By mixing and matching these modular blocks, the platform can rapidly generate ligands for any protein target, enabling proteome‑wide “chemical knockouts.” The approach reduces synthesis time to weeks and cost to a few thousand dollars while delivering biologically active compounds with low‑micromolar affinity, and is being refined toward nanomolar potency. Silicogenix demonstrates the workflow on disease‑specific programs such as Ewing sarcoma, creating novel inhibitors against the EWS‑FLI1 driver in under three months.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as academic research groups, that need fast, cost‑effective generation of custom small‑molecule therapeutics for rare diseases, oncology, and other target‑rich programs.
Features
- Library of >400 pre‑validated chemical building blocks covering major protein families (e.g., kinases) for rapid ligand assembly
- Automated design pipeline that pairs blocks with target structures to produce Target‑Ligand Pairs (TLPs) in a modular fashion
- Rapid synthesis workflow delivering candidate molecules in weeks for <$5,000 per project
- Proven biological activity with concentration‑dependent inhibition and low‑micromolar Kd; platform being tuned for nanomolar affinity
- Scalable “mix‑and‑match” capability to address patient‑specific and disease‑specific heterogeneity across multiple therapeutic areas
- Integrated computational tools for proteome‑wide target selection and ligand optimization